Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer
Phase 2
Completed
- Conditions
- Ovarian Neoplasms
- Registration Number
- NCT00038428
- Lead Sponsor
- Telik
- Brief Summary
The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every week in the treatment of patients with advanced ovarian cancer that is resistant to platinum-based chemotherapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
USC/Norris Comprehensive Cancer Center
🇺🇸Los Angeles, California, United States
M.D. Anderson Cancer Center
🇺🇸Houston, Texas, United States
Memorial Sloan-Kettering Cancer Center
🇺🇸New York, New York, United States